Opko Health (NASDAQ:OPK) issued its quarterly earnings data on Friday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03, Briefing.com reports. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The business had revenue of $250.00 million during the quarter, compared to analyst estimates of $264.04 million. During the same period in the prior year, the company posted ($0.08) EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year.
NASDAQ OPK traded down $0.40 on Friday, reaching $3.09. 7,341,070 shares of the stock traded hands, compared to its average volume of 3,831,201. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.90 and a current ratio of 1.05. The firm has a market cap of $2.16 billion, a P/E ratio of -10.66 and a beta of 1.89. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.40.
In related news, CEO Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock in a transaction dated Monday, August 13th. The stock was acquired at an average cost of $5.33 per share, with a total value of $79,950.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $16,357,508.83. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 70,000 shares of company stock valued at $392,950. Corporate insiders own 42.74% of the company’s stock.
A number of brokerages have issued reports on OPK. BidaskClub raised Opko Health from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Opko Health in a research note on Tuesday, August 7th. ValuEngine raised Opko Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 2nd. Finally, Barrington Research reaffirmed a “buy” rating and set a $7.00 price target on shares of Opko Health in a research note on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $9.69.
ILLEGAL ACTIVITY NOTICE: “Opko Health (OPK) Issues Earnings Results, Beats Estimates By $0.03 EPS” was originally published by Macon Daily and is owned by of Macon Daily. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://macondaily.com/2018/11/10/opko-health-opk-issues-earnings-results-beats-estimates-by-0-03-eps.html.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.